Keywords
Salivary glands
Keratoconjunctivitis sicca
Autoimmunity
Lymphocytes
How to Cite
Abstract
Sjögren’s syndrome is a chronic autoimmune disorder that affects the secretory glands, mainly salivary and lacrimal glands; and also can present extraglandular systemic manifestations. The objective of this review was to check the literature about the general aspects of Sjorgen's syndrome, for which a search of the literature was carried out between January 15 to March 15, 2020, 29 articles were obtained on which did the review. Sjögren’s syndrome is highly prevalent among the most common autoimmune diseases, characterized by xerostomia and xerophthalmia. The diagnostic criteria have high sensitivity and specificity, and their treatment is symptomatic.
References
Guerrero PG, Mora VL, Vaca FS. Síndrome de Sjögren primario y enfermedad quística pulmonar: reporte de un caso. MC. 2018 ; 26(2):85-88.
Bolognia JL. Dermatología. 4ª ed. Elsevier España, 2019; 728.
Vivino FB. Sjogren's syndrome: Clinical aspects. Clin Immunol. 2017;182:48-54.
Ladino RM, Gasitulli OA, Campos MX. Síndrome de Sjögren. Caso clínico. Rev Chil Pediatr. 2015;86(1):47-51.
Harris VM, Scofield RH, Sivils KL. Genetics in Sjögren’s syndrome: where we are and where we go. Clin Exp Rheumatol. 2019; 37 suppl 118(3):234–239.
Fernández-Ávila DG, Rincón-Riaño DN, BernalMacías S, Gutiérrez Dávila JM, Rosselli D. Prevalence and demographic characteristics of Sjögren’s syndrome in Colombia, based on information from the official Ministry of Health registry. Reumatol Clín. 2020; 16(4):286–289.
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74(11):1983-1989.
Amador J. Características clínicas y sociodemográficas de pacientes colombianos con Síndrome de Sjögren solo y asociados a otras enfermedades autoinmunes. Trabajo de grado. Colombia. Repositorio URosario. 2013.
Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016; 2: 544-547.
Romão VC, Talarico R, Scirè CA, et al. Sjögren’s syndrome: state of the art on clinical practice guidelines. RMD Open.2018;4:1-8.
Anaya JM, Sarmiento-Monroy JC, García-Carrasco M. Síndrome de Sjögren. Bogotá. Universidad del Rosario;2017.
Grossman S, Tagliavini LB. Managing Sjogren’s Syndrome. Home Healthc Now. 2015; 33(9):487- 492.
Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM HLA and Sjögren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012;11(4):281-7.
Both T, Dalm VASH, van Hagen PM, van Daele PLA. Reviewing primary Sjögren’s syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14(3):191–200.
Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2013;9(9):544-556.
Zheng L, Zhang Z, Yu C, Yang C. Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(6):844-850.
Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72(5):728-735.
Quartuccio L, Salvin S, Corazza L, Gandolfo S, Fabris M, De Vita S. Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol. 2016;34(2):311-314.
Patel R, Shahane A. The epidemiology of Sjögren's syndrome. Clin Epidemiol.2014;6:247-255.
Martínez JP, Reyes Y. Síndrome de Sjögren. Rev cubana med . 2010;49(2).
Brito P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, et al. Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol. 2016;12(2):137-156.
Ienopoli S, Carsons SE. Extraglandular Manifestations of Primary Sjögren’s Syndrome. Oral Maxillofac Surg Clin North Am. 2014;26(1):91-99.
Usarbarrena Ekiza Maider. Valoración médicolaboral del trabajador con Síndrome de Sjögren. Med. segur. trab. 2014; 60(234):108-132.
Ruiz Gutiérrez L, Pérez Gómez A, Pretel Ruiz P, Barrio Nogal L. Síndrome de Sjögren. Medicine. 2017 ; 12(28):1639–1644.
Martínez VA, Leal CA, Moreno DC. Alteraciones hematológicas como manifestación inicial del síndrome de Sjögren primario. Rev Colomb Reumatol. 2018;25(1):55-58.
Le Goff M, Cornec D, Jousse-Joulin S, Guellec D, Costa S, Marhadour T, et al. Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren’s syndrome. Arthritis Res Ther. 2017;19(1):269.
Ríos GBBE, Saldarriaga RLM, de Almeida TH, Leitão de Azevedo MN. Síndrome de Sjögren juvenil primario: Estudio de cohorte. Rev Cub de Reu. 2015;17(1):40-47.
Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren ́s syndrome: A twelve-week randomized, doubleblind, placebo-controlled pilot clinical trial. Arthritis Rheumatol. 2004;50(7):2240-2245.
Mairette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren ́s syndrome: results of the randomized trial. Arthritis Rheum. 2004; 50(4):1270-1276.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Médicas UIS